"Our 18 to 21% RRR is actually well ahead of many other cardiovascular disease drugs. I know this is not an apples to apples comparison...but take it for what it is."
Yes, 18-21% is really good, especially in the high-risk diabetic low-HDL recent ACS patient population. Too bad BETonMACE was underpowered to hit w/ statistical significance at this lower RRR.
BDAZ